Paliperidone Palmitate-induced Urinary Incontinence: A Case Report
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Urinary incontinence, although rarely reported, is one of the most important adverse effects of antipsychotic medication. It can be an embarrassing, distressing, and potentially treatment-limiting. Several antipsychotics, including both typical and atypical varieties, are known to induce urinary incontinence. Many antipsychotic drugs target the neural pathways controlling continence by binding to receptors of some neurotransmitters such as serotonin, dopamine, acetylcholine, and adrenaline. Pharmacological management of incontinence should be considered if there is a risk of cessation of the antipsychotic therapy or any decline in patients' compliance. Amitriptyline, desmopressin, ephedrine, and anticholinergics such as oxybutynin and trihexyphenidyl are the most frequently used agents to treat incontinence. We think that the frequency of incontinence is higher than reported in the literature, and that follow-up routines should include a form of standardized screening for all possible adverse effects, including incontinence, of any given antipsychotic. In this article, we report a case of urinary incontinence as an adverse effect of paliperidone palmitate use during maintenance therapy in a patient with schizophrenia.
Abstract
Urinary incontinence, although rarely reported, is one of the most important adverse effects of antipsychotic medication. It can be an embarrassing, distressing, and potentially treatment-limiting. Several antipsychotics, including both typical and atypical varieties, are known to induce urinary incontinence. Many antipsychotic drugs target the neural pathways controlling continence by binding to receptors of some neurotransmitters such as serotonin, dopamine, acetylcholine, and adrenaline. Pharmacological management of incontinence should be considered if there is a risk of cessation of the antipsychotic therapy or any decline in patients' compliance. Amitriptyline, desmopressin, ephedrine, and anticholinergics such as oxybutynin and trihexyphenidyl are the most frequently used agents to treat incontinence. We think that the frequency of incontinence is higher than reported in the literature, and that follow-up routines should include a form of standardized screening for all possible adverse effects, including incontinence, of any given antipsychotic. In this article, we report a case of urinary incontinence as an adverse effect of paliperidone palmitate use during maintenance therapy in a patient with schizophrenia.
참고문헌 (41)
- Pandina GJ, "A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia", J Clin Psychopharmacol, 30, pp.235~244 (2010)
- Dolder C, "Paliperidone for schizophrenia", Am J Health Syst Pharm, 65, pp.403~413 (2008)
- Bishara D, "Once-monthly paliperidone injection for the treatment of schizophrenia", Neuropsychiatr Dis Treat, 6, pp.561~572 (2010)
- Leysen JE, "Risperidone:a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity", J Clin Psychiatry, 55(Suppl), pp.5~12 (1994)
- Schotte A, "Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding", Psychopharmacology (Berl), 124, pp.57~73 (1996)
- van Beijsterveldt LE, "Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat", Psychopharmacology (Berl), 114, pp.53~62 (1994)
- Kramer M, "Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study", Int J Neuropsychopharmacol, 13, pp.635~647 (2010)
- Samtani MN, "Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic", Clin Pharmacokinet, 48, pp.585~600 (2009)
- Sedky K, "Paliperidonepalmitate:once-monthly treatment option for schizophrenia", Current Psychiatry (Online), 9, pp.48~50 (2010)
- Gopal S, "A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia", J Psychopharmacol, 25, pp.685~697 (2011)
- Nasrallah HA, "A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia", Neuropsychopharmacology, 35, pp.2072~2082 (2010)
- Hough D, "Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia:a randomized, double-blind, placebo-controlled study", Schizophr Res, 116, pp.107~117 (2010)
- Gopal S, "A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia", Innov Clin Neurosci, 8, pp.26~33 (2011)
- Fleischhacker WW, "Second-generation antipsychotic longacting injections: systematic review", Br J Psychiatry Suppl, 52, pp.S29~S36 (2009)
- Citrome L, "Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication", Int J Clin Pract, 64, pp.216~239 (2010)
- Coppola D, "A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia", BMC Psychiatry, 12, pp.26~ (2012)
- Bossie CA, "Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial", BMC Psychiatry, 11, pp.79~ (2011)
- Pandina G, "A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 35, pp.218~226 (2011)
- Nussbaum AM, "Paliperidone palmitate for schizophrenia", Schizophr Bull, 38, pp.1124~1127 (2012)
- Kantrowitz J, "Paliperidone: the evidence of its therapeutic value in schizophrenia", Core Evid, 2, pp.261~271 (2008)
- Pani L, "Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release", Expert Opin Drug Deliv, 6, pp.319~331 (2009)
- Clark N, "Conventional antipsychotic and clozapine-induced urinary incontinence", JCPNP, 2, pp.1~8 (2003)
- Ambrosini PJ, "Enuresis and incontinence occurring with neuroleptics", Am J Psychiatry, 137, pp.1278~1279 (1980)
- Shapiro AK, "Pimozide-induced enuresis", Am J Psychiatry, 138, pp.123~124 (1981)
- Kiruluta HG, "Urinary incontinence secondary to drugs", Urology, 22, pp.88~90 (1983)
- Ambrosini PJ, "A pharmacological paradigm for urinary incontinence and enuresis", J Clin Psychopharmacol, 4, pp.247~253 (1984)
- Harrison-Woolrych M, "Nocturnal enuresis in patients taking clozapine, risperidone, olanzapine and quetiapine: comparative cohort study", Br J Psychiatry, 199, pp.140~144 (2011)
- Barnes TR, "Nocturnal enuresis with antipsychotic medication", Br J Psychiatry, 200, pp.7~9 (2012)
- Mendhekar D, "Urinary incontinence associated with amisulpride", World J Biol Psychiatry, 10, pp.1045~1046 (2009)
- Bozkurt H, "Aripiprazole-induced enuresis in a child with autistic disorder", Arch Neuropsychiatry, 48, pp.164~166 (2011)
- Vera PL, "Effects of two atypical neuroleptics, olanzapine and risperidone, on the function of the urinary bladder and the external urethral sphincter in anesthetized rats", BMC Pharmacol, 1, pp.4~ (2001)
- Fuller MA, "Clozapine-induced urinary incontinence:incidence and treatment with ephedrine", J Clin Psychiatry, 57, pp.514~518 (1996)
- Mendhekar DN, "Risperidone-related reversal of primary enuresis: an unusual case report", World J Biol Psychiatry, 11, pp.514~515 (2010)
- Aronowitz JS, "Management of clozapine-induced enuresis", Am J Psychiatry, 152, pp.472~ (1995)
- Kantrowitz JT, "Three cases of risperidoneinduced enuresis", Schizophr Res, 84, pp.174~175 (2006)
- Tonini M, "5-HT4 receptor agonists and bladder disorders", Trends Pharmacol Sci, 17, pp.314~316 (1996)
- Steingard S, "Use of desmopressin to treat clozapine-induced nocturnal enuresis", J Clin Psychiatry, 55, pp.315~316 (1994)
- Poyurovsky M, "Trihexyphenidyl as a possible therapeutic option in clozapine-induced nocturnal enuresis", Int Clin Psychopharmacol, 11, pp.61~63 (1996)
- Lurie SN, "Oxybutynin and intranasal desmopressin for clozapine-induced urinary incontinence", J Clin Psychiatry, 58, pp.404~ (1997)
- Aggarwal A, "Trihexyphenidyl (benzhexol)in clozapine-induced nocturnal enuresis and sialorrhea", Indian J Med Sci, 63, pp.470~471 (2009)
- Kreder KJ, "Solifenacin", Urol Clin North Am, 33, pp.483~490 (2006)